Panxia Wang

1.1k total citations
40 papers, 943 citations indexed

About

Panxia Wang is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Panxia Wang has authored 40 papers receiving a total of 943 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 19 papers in Cardiology and Cardiovascular Medicine and 12 papers in Oncology. Recurrent topics in Panxia Wang's work include Chemotherapy-induced cardiotoxicity and mitigation (9 papers), Autophagy in Disease and Therapy (6 papers) and Signaling Pathways in Disease (6 papers). Panxia Wang is often cited by papers focused on Chemotherapy-induced cardiotoxicity and mitigation (9 papers), Autophagy in Disease and Therapy (6 papers) and Signaling Pathways in Disease (6 papers). Panxia Wang collaborates with scholars based in China, United States and Norway. Panxia Wang's co-authors include Jing Lü, Peiqing Liu, Yuehuai Hu, Junjian Wang, Peiqing Liu, Zhen Guo, Jingyan Li, Duanping Sun, Zhenzhen Li and Zhuoming Li and has published in prestigious journals such as Journal of Cell Science, Cell Death and Differentiation and British Journal of Pharmacology.

In The Last Decade

Panxia Wang

37 papers receiving 939 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Panxia Wang China 21 582 254 156 147 86 40 943
Zhen Guo China 17 582 1.0× 273 1.1× 176 1.1× 193 1.3× 66 0.8× 33 966
Lang Hong China 14 378 0.6× 450 1.8× 164 1.1× 104 0.7× 81 0.9× 35 939
Liang Shao China 16 438 0.8× 458 1.8× 171 1.1× 103 0.7× 81 0.9× 48 1.1k
Anantha Koteswararao Kanugula India 16 494 0.8× 85 0.3× 89 0.6× 140 1.0× 101 1.2× 23 1.0k
Zhang Ping China 15 387 0.7× 403 1.6× 170 1.1× 83 0.6× 60 0.7× 31 974
Xinyong Cai China 14 423 0.7× 403 1.6× 153 1.0× 167 1.1× 56 0.7× 35 960
Santosh Karnewar India 19 718 1.2× 101 0.4× 109 0.7× 189 1.3× 166 1.9× 27 1.5k
Rongjun Zou China 15 547 0.9× 201 0.8× 70 0.4× 167 1.1× 191 2.2× 50 1.0k
Yuehuai Hu China 12 264 0.5× 146 0.6× 76 0.5× 50 0.3× 41 0.5× 16 464
Zuhong Tian China 12 373 0.6× 61 0.2× 92 0.6× 138 0.9× 92 1.1× 20 715

Countries citing papers authored by Panxia Wang

Since Specialization
Citations

This map shows the geographic impact of Panxia Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Panxia Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Panxia Wang more than expected).

Fields of papers citing papers by Panxia Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Panxia Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Panxia Wang. The network helps show where Panxia Wang may publish in the future.

Co-authorship network of co-authors of Panxia Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Panxia Wang. A scholar is included among the top collaborators of Panxia Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Panxia Wang. Panxia Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Hong, Jianxing Chen, Yuemei Wang, et al.. (2025). SNX3 mediates heart failure by interacting with HMGB1 and subsequently facilitating its nuclear-cytoplasmic translocation. Acta Pharmacologica Sinica. 46(4). 964–975.
2.
Zhou, Kun, Hui Cai, Q. Li, et al.. (2025). Nobiletin protected against hypertrophic cardiomyopathy via targeting PPARα. Frontiers in Pharmacology. 16. 1628625–1628625.
3.
Yang, Bowen, Xiaohong Wang, Yan Li, et al.. (2025). Magnetic resonance imaging features of epididymal and/or testicular tuberculosis: a case series. BMC Medical Imaging. 25(1). 157–157. 1 indexed citations
4.
Li, Wenting, Qian Li, Yiqi Jiang, et al.. (2025). The Dual Role and Therapeutic Implications of the Wnt/β-Catenin Pathway in Diabetic Kidney Disease. International Journal of General Medicine. Volume 18. 2757–2768. 1 indexed citations
5.
Jiang, Feng, et al.. (2025). Traditional Chinese medicine protects against doxorubicin cardiotoxicity via epigenetic modification and beyond. Phytomedicine. 145. 157020–157020. 1 indexed citations
6.
Wang, Wei, Mingyan Li, Zhimin Gao, et al.. (2025). RAB7 protects against ischemic heart failure via promoting non-canonical TUFM mitophagy pathway. Theranostics. 15(14). 6753–6767.
7.
Sun, Lu, et al.. (2024). Dehydroandrographolide ameliorates doxorubicin-mediated cardiotoxicity by regulating autophagy through the mTOR-TFEB pathway. Chemico-Biological Interactions. 399. 111132–111132. 5 indexed citations
8.
Hu, Yuehuai, Cui Liu, Ying Wu, et al.. (2024). Mitochondrial MOF regulates energy metabolism in heart failure via ATP5B hyperacetylation. Cell Reports. 43(10). 114839–114839. 8 indexed citations
9.
Wang, Panxia, Luping Wang, Cui Liu, et al.. (2024). YAP K236 acetylation facilitates its nucleic export and deprived the protection against cardiac hypertrophy in mice. Pharmacological Research. 211. 107573–107573. 2 indexed citations
10.
Wang, Panxia, Yuansheng Xu, Quan Wang, et al.. (2022). Trypsin inhibitor LH011 inhibited DSS-induced mice colitis via alleviating inflammation and oxidative stress. Frontiers in Pharmacology. 13. 986510–986510. 8 indexed citations
11.
Wang, Luping, Panxia Wang, Suowen Xu, et al.. (2021). The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy. International Journal of Biological Sciences. 18(2). 783–799. 8 indexed citations
12.
Zheng, Jianwei, Junfeng Wang, Qian Wang, et al.. (2020). Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin. Acta Pharmaceutica Sinica B. 10(12). 2313–2322. 26 indexed citations
13.
Wei, Jinxing, Lihong Lv, Qingfang Han, et al.. (2020). Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. Cell Communication and Signaling. 18(1). 46–46. 78 indexed citations
14.
Hu, Yuehuai, Jing Lü, Panxia Wang, et al.. (2020). sFRP1 protects H9c2 cardiac myoblasts from doxorubicin-induced apoptosis by inhibiting the Wnt/PCP-JNK pathway. Acta Pharmacologica Sinica. 41(9). 1150–1157. 24 indexed citations
15.
Ding, Yan-qing, Yuhong Zhang, Jing Lü, et al.. (2020). MicroRNA-214 contributes to Ang II-induced cardiac hypertrophy by targeting SIRT3 to provoke mitochondrial malfunction. Acta Pharmacologica Sinica. 42(9). 1422–1436. 35 indexed citations
16.
Wang, Panxia, Minghui Wang, Yuehuai Hu, et al.. (2020). Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression. Acta Pharmaceutica Sinica B. 11(3). 680–693. 44 indexed citations
17.
Li, Zhenzhen, Xiaoying Zhang, Zhen Guo, et al.. (2019). SIRT6 Suppresses NFATc4 Expression and Activation in Cardiomyocyte Hypertrophy. Frontiers in Pharmacology. 9. 1519–1519. 31 indexed citations
18.
Liu, Yajun, Jing Lü, Jing Yuan, et al.. (2018). Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway. Naunyn-Schmiedeberg s Archives of Pharmacology. 391(12). 1373–1385. 26 indexed citations
19.
Lü, Jing, Jingyan Li, Yuehuai Hu, et al.. (2018). Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation. Acta Pharmaceutica Sinica B. 9(4). 782–793. 45 indexed citations
20.
Wang, Panxia, Zhuo-ming Li, Jingyan Li, et al.. (2017). C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling. Acta Pharmacologica Sinica. 38(9). 1257–1268. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhen Guo Breakdown of academic impact, for papers by Lang Hong Breakdown of academic impact, for papers by Liang Shao Breakdown of academic impact, for papers by Anantha Koteswararao Kanugula Breakdown of academic impact, for papers by Zhang Ping Breakdown of academic impact, for papers by Xinyong Cai Breakdown of academic impact, for papers by Santosh Karnewar Breakdown of academic impact, for papers by Rongjun Zou Breakdown of academic impact, for papers by Yuehuai Hu Breakdown of academic impact, for papers by Zuhong Tian
Rankless by CCL
2026